Evidence map›Paper›PMID 31159367›Full record

ArticleMolecules (Basel, Switzerland)2019

Exploring

Matthias Engleder, Monika Müller, Iwona Kaluzna, Daniel Mink, Martin Schürmann, Erich Leitner, Harald Pichler, Anita Emmerstorfer-Augustin

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Matthias EnglederAustrian Centre of Industrial Biotechnology, Petersgasse 14, 8010 Graz, Austria. matthias.engleder@acib.at.ORCID 0000-0002-1064-1018
Monika MüllerInnoSyn B.V., Urmonderbaan 22, 6167 RD Geleen, The Netherlands. monika.muller@innosyn.com.
Iwona KaluznaInnoSyn B.V., Urmonderbaan 22, 6167 RD Geleen, The Netherlands. iwona.kaluzna@innosyn.com.
Daniel MinkInnoSyn B.V., Urmonderbaan 22, 6167 RD Geleen, The Netherlands. daniel.mink@innosyn.com.
Martin SchürmannInnoSyn B.V., Urmonderbaan 22, 6167 RD Geleen, The Netherlands. martin.schuermann@innosyn.com.
Erich LeitnerAustrian Centre of Industrial Biotechnology, Petersgasse 14, 8010 Graz, Austria. erich.leitner@tugraz.at.ORCID 0000-0003-2520-2111
Harald PichlerAustrian Centre of Industrial Biotechnology, Petersgasse 14, 8010 Graz, Austria. harald.pichler@tugraz.at.ORCID 0000-0001-6043-2137
Anita Emmerstorfer-AugustinAustrian Centre of Industrial Biotechnology, Petersgasse 14, 8010 Graz, Austria. emmerstorfer-augustin@tugraz.at.
Institute of Molecular Biotechnology · ATGraz University of Technology · AT

Funding

Austrian Science Fund J3787
6 · The paper itself

Abstract

Acyclic monoterpenes constitute a large and highly abundant class of secondary plant metabolites and are, therefore, attractive low-cost raw materials for the chemical industry. To date, numerous biocatalysts for their transformation are known, giving access to highly sought-after monoterpenoids. In view of the high selectivity associated with many of these reactions, the demand for enzymes generating commercially important target molecules is unabated. Here, linalool (de)hydratase-isomerase (Ldi, EC 4.2.1.127) from

Indexed as

Acyclic MonoterpenesAlcoholsAlkenesBetaproteobacteriaCatalysisEscherichia coliHydro-LyasesHydrolysisIsomerasesMonoterpenesAcyclic MonoterpenesAlcoholsAlkenesHydro-LyasesIsomeraseslinaloolMonoterpenesCastellaniella defragransdehydratasegeraniolhydrataseisomeraselinaloolmonoterpene hydrationmyrcenetertiary alcohol

Identifiers

PMID31159367
PMCPMC6600392
OpenAlexW2947235560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.